Kolon TissueGene, Inc. Logo

Kolon TissueGene, Inc.

A clinical-stage biopharma developing cell and gene therapies for orthopedic diseases.

950160 | KO

Overview

Corporate Details

ISIN(s):
KR8840120008
LEI:
Country:
United States of America
Address:
9713 Key West Ave Suite 300, Rockville

Description

Kolon TissueGene, Inc. is a clinical-stage biopharmaceutical company specializing in the development of advanced cell and gene therapies for orthopedic diseases and degenerative disorders. The company's lead product candidate, TG-C, is a first-in-class, allogeneic cell and gene therapy designed to treat knee osteoarthritis. The therapy aims to reduce pain, improve joint function, and slow the progression of the disease. TG-C is currently in late-stage clinical development, undergoing Phase 3 trials.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-03-13 00:00
주주총회소집공고
Korean 136.5 KB
2023-02-10 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 16.4 KB
2022-12-13 00:00
기타경영사항(자율공시)(제24기 정기주주총회 권리주주 확정을 위한 증권예탁증권(KDR) 기준일 설정 공고)
Korean 5.1 KB
2022-11-14 00:00
분기보고서 (2022.09)
Korean 1.0 MB
2022-10-24 00:00
기타시장안내(위원회 심의결과 및 상장유지 결정 안내)
Korean 3.1 KB
2022-10-24 00:00
주권매매거래정지해제(상장유지 결정)
Korean 4.3 KB
2022-10-24 00:00
기타경영사항(자율공시)(최대주주 등의 보유주식에 대한 자발적 의무보유 시행 및 당사 자금조달계획에 대한 최대주주의 지원 확약)
Korean 8.4 KB
2022-10-21 00:00
수시공시의무관련사항(공정공시)(유상증자 계획)
Korean 5.8 KB
2022-09-23 00:00
기타시장안내(개선계획 이행내역서 제출)
Korean 3.2 KB
2022-09-16 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.7 KB
2022-09-07 00:00
증권발행결과(자율공시)(제1회차 CB)
Korean 6.1 KB
2022-09-02 00:00
주식등의대량보유상황보고서(일반)
Korean 121.1 KB
2022-09-02 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 23.1 KB
2022-09-02 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 23.1 KB
2022-09-02 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.8 KB

Automate Your Workflow. Get a real-time feed of all Kolon TissueGene, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kolon TissueGene, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kolon TissueGene, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Aldeyra Therapeutics, Inc. Logo
Develops medications for immune-mediated ocular and systemic diseases.
United States of America
ALDX
Alector, Inc. Logo
Clinical-stage biotech using immuno-neurology to treat neurodegenerative diseases.
United States of America
ALEC
ALK-Abelló Logo
A pharmaceutical company specializing in allergy prevention, diagnosis, and treatment.
Denmark
ALK
Alkaloid AD Logo
Manufactures generic pharmaceuticals, cosmetics, and chemical products.
North Macedonia
ALK
Alkermes plc. Logo
Develops and commercializes medicines for central nervous system (CNS) diseases.
United States of America
ALKS
Allarity Therapeutics, Inc. Logo
A clinical-stage biopharma using diagnostics to develop targeted cancer therapies.
United States of America
ALLR
ALLERGY THERAPEUTICS PLC Logo
Immunology company developing aluminum-free vaccines and therapies for allergies.
United Kingdom
AGY
Alligator Bioscience Logo
Clinical-stage biotech developing tumor-directed immuno-oncology antibody drugs.
Sweden
ATORX
Allogene Therapeutics, Inc. Logo
Develops off-the-shelf allogeneic CAR T therapies for cancer and autoimmune diseases.
United States of America
ALLO
Almirall S.A. Logo
Global biopharmaceutical company specializing in medical dermatology and skin health.
Spain
ALM

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.